GHRH receptor
Tesamorelin has been investigated as an agonist at the pituitary GHRH receptor.
Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
Tesamorelin10 mg
Lyophilized Peptide — Single vial
Tesamorelin 10 mg supplied exclusively as a laboratory research material. Available batch documentation is published only under its corresponding batch record.
Out of stock
Pricing confirmed separately
- RESEARCH FOCUS
- Growth Hormone & Body Composition
QUANTITY
Research areas
FOR LABORATORY RESEARCH USE ONLY.
VERIFY BATCH →Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
RESEARCH & TECHNICAL OVERVIEW
Tesamorelin
10 mg
Tesamorelin (TH9507) is a synthetic, N-terminally modified analogue of the 44-amino-acid human growth-hormone-releasing hormone (GHRH). It was designed to retain GHRH-receptor activity while changing peptide stability characteristics.
Research has examined pituitary GHRH-receptor signalling, pulsatile growth-hormone release and downstream IGF-1 responses. Published human studies are cited as research context, not as instructions or claims for this NOREXA material.
RESEARCH SCOPE
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
HANDLING INFORMATION
Storage After
Reconstitution.
- Formulation dependent
- Published tesamorelin formulations use different post-reconstitution storage conditions. A formulation-specific storage recommendation has not been established for NOREXA Tesamorelin 10 mg.
SCIENTIFIC CONTEXT
Structured.
Source-led.
Longer technical information is grouped for easier reading on desktop and mobile.
01Natural Biological Context+
Human GHRH is an endogenous hypothalamic peptide that participates in the physiological regulation of pulsatile growth-hormone secretion. Tesamorelin is synthetic and should be distinguished from the native hormone.
02Research Mechanisms+
GH pulsatility
Controlled human research has measured changes in endogenous growth-hormone pulse area and basal secretion.
IGF-1 signalling
Downstream IGF-1 responses have been monitored as part of GHRH-axis research.
03Research Applications+
- GHRH-receptor and pituitary signalling research.
- Endocrine pulse analysis involving growth hormone and IGF-1 biomarkers.
- Published human metabolic and body-composition research in defined study populations.
04Laboratory Research Preparation+
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Batch evidence,
without overclaiming.
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
CURRENT BATCH / LOT
Independent batch verification: report not currently published
No identity, purity, quantity or batch number is shown as independently verified until exact product-and-lot evidence is available.
OPEN CENTRAL BATCH VERIFICATION →HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Technical
Data.
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
- Product Name
- Tesamorelin
- Content
- 10 mg
- Form
- Lyophilized Peptide
- Presentation
- Single vial
- CAS Number
- 218949-48-5
- Synonym
- TH9507
- Peptide Sequence
- YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
- Molecular Formula
- C221H366N72O67S
- Molecular Weight
- 5136 g/mol
- Research Classification
- Research Use Only
Batch documentation and independent reports are shown only when published for the exact corresponding batch.
CHEMICAL IDENTITY REFERENCE ↗SELECTED SOURCES
Research
Literature.
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
- 01Human research↗
Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men
Journal of Clinical Endocrinology & Metabolism · 2011
- 02Human research↗
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
JAMA · 2014
- 03Human research↗
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue
AIDS · 2008
PRODUCT FAQ
Tesamorelin
questions.
01Is Tesamorelin the same as natural GHRH?+
No. Tesamorelin is a synthetic modified analogue of human GHRH.
02What pathway is studied?+
Research focuses on the GHRH receptor, endogenous growth-hormone pulsatility and downstream IGF-1 signalling.
03Why is the storage guidance formulation dependent?+
Published tesamorelin formulations use different post-reconstitution storage conditions. A formulation-specific recommendation has not been established for NOREXA Tesamorelin 10 mg.
04Is there a published independent batch report?+
Not currently on this page. A report will be shown only when it belongs to the exact product batch.
SECTION 01 — STANDARDS
Scientific transparency,
documented for research.
01 / 03Scientific Integrity
Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Batch Traceability
Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Quality Documentation
Available batch documentation is organized under the corresponding batch number for clear reference.